Inozyme Pharma, Inc. (INZY)
Jul 1, 2025 - INZY was delisted (reason: acquired by BMRN)
4.000
0.00 (0.00%)
Inactive · Last trade price on Jun 30, 2025

Company Description

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function.

The company’s lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis.

It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway.

The company has license agreement with Yale University for specified therapeutic and prophylactic products.

Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. As of July 1, 2025, Inozyme Pharma, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc..

Inozyme Pharma, Inc.
Inozyme Pharma logo
Country United States
Founded 2015
IPO Date Jul 24, 2020
Industry Biotechnology
Sector Healthcare
Employees 67
CEO Douglas Treco

Contact Details

Address:
321 Summer Street
Boston, Delaware 02210
United States
Phone 857 330 4340
Website inozyme.com

Stock Details

Ticker Symbol INZY
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001693011
CUSIP Number 45790W108
ISIN Number US45790W1080
Employer ID 47-5129768
SIC Code 2836

Key Executives

Name Position
Dr. Douglas A. Treco Ph.D. Chief Executive Officer and Chairman
Axel Bolte M.B.A., M.Sc. Co-Founder, Senior Advisor and Director
Sanjay S. Subramanian M.B.A., M.S. Chief Financial Officer, Head of Business Development, Principal Accounting Officer and Corporate Secretary
Dr. Matthew Winton Ph.D. Senior Vice President and Chief Operating Officer
Dr. Demetrios Braddock M.D., Ph.D. Co-Founder, Scientific Founder, Member of Scientific Advisory Board and Board Observer
Dr. Yves Sabbagh Ph.D. Senior Vice President, Chief Scientific Officer and Chair of the Scientific Advisory Board
Stefan Riley Director of Investor Relations
Gayle Gironda Senior Vice President and Chief People Officer
Stephen J. Di Palma M.B.A. Consultant
Dr. Petra Duda M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Jul 1, 2025 EFFECT Notice of Effectiveness
Jul 1, 2025 EFFECT Notice of Effectiveness
Jul 1, 2025 25-NSE Filing
Jul 1, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 1, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 1, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 1, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 1, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 1, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 1, 2025 POS AM Post-Effective amendments for registration statement